Obstetric antiphospholipid syndrome
Copyright policy )Obstetric antiphospholipid syndrome
Antiphospholipid syndrome (APS) in pregnancy has a serious impact on maternal and fetal morbidity. It causes recurrent pregnancy miscarriage and it is associated with other adverse obstetric findings like preterm delivery, intrauterine growth restriction, preeclampsia, HELLP syndrome and others. The 2006 revised criteria, which is still valid, is used for APS classification. Epidemiology of obstetric APS varies from one population group to another largely due to different inclusion criteria and lack of standardization of antibody detection methods. Treatment is still controversial. This topic should include a multidisciplinary team and should be individualized. Success here is based on strict control and monitoring throughout pregnancy and even in the preconception and postpartum periods. Further research in this field and unification of criteria are required to yield better therapeutic strategies in the future.
- Universidad de San Buenaventura, Bogota Colombia
- Universidad del Rosario Colombia
Dalteparin, Unclassified drug, Antithrombin, Review, Betamethasone, Dexamethasone, Mice, Autoantibody, Teratogenicity, Pregnancy, habitual, Antiphospholipid syndrome, Autoimmune disease, animal, Precision Medicine, Individualized medicine, Beta 2 glycoprotein 1 antibody, Low molecular weight heparin, Lupus anticoagulant, Nadroparin, Puerperium, Blood coagulation, Cardiolipin antibody, Antiphospholipid Syndrome, antiphospholipid, Antibodies, Antiphospholipid, Female, Immunotherapy, Human, Laboratory test, Abortion, Habitual, Obstetric antiphospholipid syndrome, Prednisolone, Disease models, Vascular disease, Antibodies, Low drug dose, Hypercoagulability, Antibody-dependent cell cytotoxicity, Acetylsalicylic acid, Animals, Humans, Enoxaparin, Blood Coagulation, Antibody, Spontaneous abortion, Aspirin, Heparin, Antiphospholipid antibodies, Abortion, Antibody-Dependent Cell Cytotoxicity, Thrombosis, Nonhuman, Standardization, Pregnancy Complications, Antibody detection, Disease Models, Animal, Pregnancy complications, Recurrent pregnancy miscarriage, Prednisone, Preconception injury, Warfarin, Morbidity
Dalteparin, Unclassified drug, Antithrombin, Review, Betamethasone, Dexamethasone, Mice, Autoantibody, Teratogenicity, Pregnancy, habitual, Antiphospholipid syndrome, Autoimmune disease, animal, Precision Medicine, Individualized medicine, Beta 2 glycoprotein 1 antibody, Low molecular weight heparin, Lupus anticoagulant, Nadroparin, Puerperium, Blood coagulation, Cardiolipin antibody, Antiphospholipid Syndrome, antiphospholipid, Antibodies, Antiphospholipid, Female, Immunotherapy, Human, Laboratory test, Abortion, Habitual, Obstetric antiphospholipid syndrome, Prednisolone, Disease models, Vascular disease, Antibodies, Low drug dose, Hypercoagulability, Antibody-dependent cell cytotoxicity, Acetylsalicylic acid, Animals, Humans, Enoxaparin, Blood Coagulation, Antibody, Spontaneous abortion, Aspirin, Heparin, Antiphospholipid antibodies, Abortion, Antibody-Dependent Cell Cytotoxicity, Thrombosis, Nonhuman, Standardization, Pregnancy Complications, Antibody detection, Disease Models, Animal, Pregnancy complications, Recurrent pregnancy miscarriage, Prednisone, Preconception injury, Warfarin, Morbidity
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).66 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 10% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Top 10% impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 10%
Citations provided by BIP!Popularity provided by BIP!